ClinicalTrials.gg
Not yet recruitingNCT06254989ESAP-CSUpdated Feb 12, 2024

Effectiveness of an Aerobic Exercise Program in Cancer Survivors.

An interventional study of Aerobic Exercise in Aerobic Exercise, sponsored by Holy Name Medical Center, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-12.

Primary conditionNeoplasmsRegistry: Motor ActivityReclassifiedWhy we changed it
Registry
Motor Activity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasms
Why
  1. Motor Activity is a broad heading, used only when no more specific condition is named.
  2. The study's title name Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Holy Name Medical Center, Inc. · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A prospective study of cancer survivor patients enrolling in a pilot aerobic exercise program. The total enrollment will be fifteen patients. The study timeline includes a screening period of 4 weeks, baseline period of 2 weeks, and active study intervention for 12 weeks. Study enrollment will continue until all 15 subjects are enrolled or up to 12 months, whichever comes first.

Read the detailed description

Study Population: Adult cancer survivors within one year of completing cancer-directed therapy.

Study Objective: To determine the feasibility of a prescription exercise program in a cancer survivor population

Specific Objectives:

  1. Quantify the number of patients who successfully enroll and complete the Program.
  2. Determine a preliminary benefit, if any, of the program with regard to biometric parameters (change in systolic blood pressure, BMI, body composition, average step count, VO2 max), laboratory parameters (Hgb A1c, CRP, Lipid Profile, IL-6, Apolipoprotein B, Vitamin D-25-OH, Vitamin B12 and Folate), patient-reported wellness surveys (SEE, SRQ, Sleep Surveys).

Study Endpoints/Outcomes:

A. Percentage of participants who complete the Program. B. Change in systolic blood pressure C. Change in BMI D. Change in body composition E. Change in Average daily step count F. Change in predicted VO2 max F. Change in participant-reported wellness surveys (SEE, SRQ, and Sleep Surveys) G. Change in Circumference measurements (hip, waist, and neck) H. Improvement in laboratory parameters (Hgb A1c, CRP, Lipid profile, IL-6, Alipoprotein B, Vitamin D-25-OH, Vitamin B12, Folate) I. Cancer recurrence

Sample Size: Fifteen subjects

02

Conditions studied

  • Aerobic Exercise

Browse trials for

Keywords

  • Exercise
  • Cancer
  • Survivorship
03

In context

Neoplasms Reclassified

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 15 is below the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Holy Name Medical Center, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Motor Activity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (>18 yr.) cancer survivor patients who completed treatment within the past year and are able to physically participate in the interventional aerobic exercise program.

Exclusion criteria

Exclusion Criteria:

  • Non-ambulatory individuals
  • Inability to communicate in English
  • Lack of transportation to/from appointments (Of note, language and transportation exclusion criteria are based on practical needs for this pilot study. If effective, services would be open to a broader array of patients).
  • On medications (e.g., Ozempic, Tirzepatide) which induce prolonged weight loss.
  • Patients who received cancer-directed therapy within the past month.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Interventions

  • OtherAerobic Exercise

    Participants will engage in aerobic exercise at HNH fitness at a minimum of 2 days a week for 12 weeks. Participants will have their daily step count collected via the Fitbit during this period. VO2 measurements will also be collected during active intervention using the UNCCRI protocol. The structured aerobic exercise program (Weeks 3-14) will entail 30 minutes of aerobic activity, 3 days a week, on the treadmill, at a goal of between 50 to 70% of predicted VO2 maximum heart rate. All structured aerobic program sessions will take place at Holy Name Health (HNH) Fitness and will be overseen by our collaborator and Director of Human Performance (Reg Grant). Exercise data will be recorded in the Technogym MyWellness cloud. Participants who drop out or discontinue attendance (defined as 4 consecutive sessions missed without notification of absence) before completion of the 12-week study intervention period will be replaced.

06

What researchers measure

Primary outcomes

  1. Feasibility of providing a structured in-person aerobic exercise intervention

    To determine the feasibility of providing a structured in-person aerobic exercise training intervention to cancer survivor patients by determining the percentage of enrolled patients who complete the study.

    Time frame: 6 months

Secondary outcomes

  1. Weight in Lbs

    Change in weight (Lbs) from baseline

    Time frame: 6 months

  2. Blood Pressure in mmHg

    Change in blood pressure (mmHg) from baseline

    Time frame: 6 months

  3. Heart Rate in bpm

    Change in Heart rate (bpm) from baseline

    Time frame: 6 months

  4. Body Mass Index (BMI) in Kg/m2

    Change in BMI from baseline. BMI will be calculated as weight (kg)/height (m2).

    Time frame: 6 months

  5. Predicted VO2 max in ml/kg/min

    Change in predicted VO2 max from baseline calculated as the milliliters of Oxygen used per kg of body weight per minute

    Time frame: 6 months

  6. Percentage lean body mass

    Change in lean body mass percentage from baseline

    Time frame: 6 months

  7. Percentage visceral fat

    Change in visceral fat percentage from baseline

    Time frame: 6 months

  8. Percentage total body fat

    Change in total body fat percentage from baseline

    Time frame: 6 months

  9. Hip circumference measurement in cm

    Change in hip circumference measurements from baseline

    Time frame: 6 months

  10. Waist circumference measurement in cm

    Change in waist circumference measurements from baseline

    Time frame: 6 months

  11. Neck circumference measurements in cm

    Change in Neck circumference measurements from baseline

    Time frame: 6 months

  12. Laboratory Assessments of Nutrition, Glucose control and cardiovascular health

    Change in laboratory Assessments of Nutrition, Glucose control and cardiovascular health

    Time frame: 6 months

  13. Average daily step count

    Change in average daily step count from baseline

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254989
Lead sponsor
Holy Name Medical Center, Inc.
Responsible party
George Miller (Chief of Surgical Oncology, Holy Name Medical Center, Inc.) — Principal investigator
First posted
Feb 12, 2024
Start date
Feb 12, 2024 (estimated)
Primary completion
Feb 28, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Feb 12, 2024

Study contacts

George Miller, MD
Contact
Gemiller@holyname.org
2015307934
Dan Rector, RN
Contact
drector@holyname.org
2018334742 ext. 4742
George Miller, MD
principal investigator · Holy Name Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion